STOCK TITAN

[Form 4] C3.ai, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

MetLife, Inc. (MET) filed a Form 144 announcing a proposed sale of 547 shares of common stock through Barclays Capital on 20 June 2025. The aggregate market value of the proposed sale is $42,966.85, compared with 671,297,826 shares currently outstanding, representing roughly 0.00008 % of shares outstanding.

The filing lists prior sales over the past three months by various MetLife-related accounts totaling 686 shares and gross proceeds of about $55,392. Acquisition details show the shares were originally purchased in 2013-2014 from Deutsche Bank for cash. No adverse undisclosed information is attested by the filer, and the signature section affirms compliance with Rule 144 and Rule 10b5-1 provisions.

Given the small size of the transaction relative to MetLife’s market capitalization and float, the notice is largely administrative and unlikely to affect the company’s financial condition or share price.

MetLife, Inc. (MET) ha presentato un Modulo 144 annunciando una proposta di vendita di 547 azioni ordinarie tramite Barclays Capital il 20 giugno 2025. Il valore di mercato complessivo della vendita proposta è di 42.966,85 $, rispetto alle 671.297.826 azioni attualmente in circolazione, rappresentando circa lo 0,00008% delle azioni in circolazione.

La dichiarazione elenca vendite precedenti negli ultimi tre mesi da vari conti correlati a MetLife per un totale di 686 azioni e proventi lordi di circa 55.392 $. I dettagli sull'acquisizione mostrano che le azioni sono state originariamente acquistate nel 2013-2014 da Deutsche Bank in contanti. Il dichiarante attesta l'assenza di informazioni sfavorevoli non divulgate e la sezione della firma conferma il rispetto delle disposizioni della Regola 144 e della Regola 10b5-1.

Considerando la piccola entità della transazione rispetto alla capitalizzazione di mercato e al flottante di MetLife, la comunicazione ha principalmente carattere amministrativo ed è improbabile che influenzi la situazione finanziaria della società o il prezzo delle azioni.

MetLife, Inc. (MET) presentó un Formulario 144 anunciando una propuesta de venta de 547 acciones comunes a través de Barclays Capital el 20 de junio de 2025. El valor de mercado total de la venta propuesta es de 42,966.85 $, en comparación con las 671,297,826 acciones actualmente en circulación, representando aproximadamente el 0.00008 % de las acciones en circulación.

La presentación lista ventas previas en los últimos tres meses por varias cuentas relacionadas con MetLife que suman 686 acciones y un ingreso bruto de aproximadamente 55,392 $. Los detalles de adquisición muestran que las acciones fueron originalmente compradas en 2013-2014 a Deutsche Bank en efectivo. El declarante certifica que no hay información adversa no revelada y la sección de firma confirma el cumplimiento con las disposiciones de la Regla 144 y la Regla 10b5-1.

Dado el tamaño reducido de la transacción en relación con la capitalización de mercado y el flotante de MetLife, el aviso es principalmente administrativo y es poco probable que afecte la condición financiera de la empresa o el precio de las acciones.

MetLife, Inc. (MET)는 144 양식을 제출하여 2025년 6월 20일 Barclays Capital을 통해 547주의 보통주 매각을 제안했습니다. 제안된 매각의 총 시장 가치는 $42,966.85이며, 현재 유통 중인 671,297,826주와 비교할 때 약 0.00008%에 해당합니다.

신고서에는 지난 3개월 동안 MetLife 관련 계좌에서 총 686주를 판매하여 약 $55,392의 총수익을 올린 내역이 포함되어 있습니다. 취득 내역에 따르면 해당 주식은 2013-2014년에 Deutsche Bank로부터 현금으로 구매되었습니다. 신고자는 공개되지 않은 불리한 정보가 없음을 확인하며, 서명란에서는 Rule 144 및 Rule 10b5-1 규정 준수를 확인합니다.

MetLife의 시가총액 및 유통 주식 수에 비해 거래 규모가 매우 작기 때문에 이 공지는 주로 행정적인 성격이며 회사의 재무 상태나 주가에 영향을 미칠 가능성은 낮습니다.

MetLife, Inc. (MET) a déposé un formulaire 144 annonçant une vente proposée de 547 actions ordinaires via Barclays Capital le 20 juin 2025. La valeur marchande totale de la vente proposée s'élève à 42 966,85 $, comparée aux 671 297 826 actions actuellement en circulation, représentant environ 0,00008 % des actions en circulation.

Le dépôt indique des ventes antérieures au cours des trois derniers mois par divers comptes liés à MetLife totalisant 686 actions et des produits bruts d'environ 55 392 $. Les détails d'acquisition montrent que les actions ont été initialement achetées en 2013-2014 auprès de Deutsche Bank en espèces. Le déposant atteste qu'aucune information défavorable non divulguée n'existe, et la section de signature confirme la conformité avec les règles 144 et 10b5-1.

Étant donné la petite taille de la transaction par rapport à la capitalisation boursière et au flottant de MetLife, cet avis est principalement administratif et il est peu probable qu'il affecte la situation financière de la société ou le cours de l'action.

MetLife, Inc. (MET) hat ein Formular 144 eingereicht, in dem ein geplanter Verkauf von 547 Stammaktien über Barclays Capital am 20. Juni 2025 angekündigt wird. Der Gesamtmarktwert des geplanten Verkaufs beträgt 42.966,85 $, verglichen mit 671.297.826 ausstehenden Aktien, was etwa 0,00008 % der ausstehenden Aktien entspricht.

Die Einreichung listet frühere Verkäufe in den letzten drei Monaten durch verschiedene MetLife-nahe Konten auf, die insgesamt 686 Aktien und Bruttoerlöse von etwa 55.392 $ umfassen. Die Erwerbsdetails zeigen, dass die Aktien ursprünglich 2013-2014 von der Deutschen Bank gegen Barzahlung gekauft wurden. Der Einreicher bestätigt, dass keine nachteiligen, nicht offengelegten Informationen vorliegen, und der Unterschriftsbereich bestätigt die Einhaltung der Regel 144 und Regel 10b5-1.

Angesichts der geringen Größe der Transaktion im Verhältnis zur Marktkapitalisierung und zum Streubesitz von MetLife ist die Mitteilung hauptsächlich administrativer Natur und wird voraussichtlich weder den finanziellen Zustand des Unternehmens noch den Aktienkurs beeinflussen.

Positive
  • Transparency maintained: Management or plan trustees disclosed the planned sale in accordance with Rule 144 requirements.
  • Negligible dilution risk: 547 shares represent only 0.00008 % of outstanding shares.
Negative
  • Insider/affiliate selling, even if small, can be interpreted as a lack of incremental insider buying interest.

Insights

TL;DR: Tiny Rule 144 sale (547 MET shares, $43K) is immaterial to float or valuation.

The filing discloses an intended disposition of 547 common shares—miniscule versus the 671 million shares outstanding. Even aggregated with the past-quarter sales (686 shares), the total liquidations equal roughly $0.1 million, far below any materiality threshold for a large-cap insurer like MetLife. Such routine plan-level or employee transactions rarely signal strategic shifts or deteriorating fundamentals. Investors may note continued transparency, but the event should be classified as non-impactful to earnings, liquidity, or governance.

MetLife, Inc. (MET) ha presentato un Modulo 144 annunciando una proposta di vendita di 547 azioni ordinarie tramite Barclays Capital il 20 giugno 2025. Il valore di mercato complessivo della vendita proposta è di 42.966,85 $, rispetto alle 671.297.826 azioni attualmente in circolazione, rappresentando circa lo 0,00008% delle azioni in circolazione.

La dichiarazione elenca vendite precedenti negli ultimi tre mesi da vari conti correlati a MetLife per un totale di 686 azioni e proventi lordi di circa 55.392 $. I dettagli sull'acquisizione mostrano che le azioni sono state originariamente acquistate nel 2013-2014 da Deutsche Bank in contanti. Il dichiarante attesta l'assenza di informazioni sfavorevoli non divulgate e la sezione della firma conferma il rispetto delle disposizioni della Regola 144 e della Regola 10b5-1.

Considerando la piccola entità della transazione rispetto alla capitalizzazione di mercato e al flottante di MetLife, la comunicazione ha principalmente carattere amministrativo ed è improbabile che influenzi la situazione finanziaria della società o il prezzo delle azioni.

MetLife, Inc. (MET) presentó un Formulario 144 anunciando una propuesta de venta de 547 acciones comunes a través de Barclays Capital el 20 de junio de 2025. El valor de mercado total de la venta propuesta es de 42,966.85 $, en comparación con las 671,297,826 acciones actualmente en circulación, representando aproximadamente el 0.00008 % de las acciones en circulación.

La presentación lista ventas previas en los últimos tres meses por varias cuentas relacionadas con MetLife que suman 686 acciones y un ingreso bruto de aproximadamente 55,392 $. Los detalles de adquisición muestran que las acciones fueron originalmente compradas en 2013-2014 a Deutsche Bank en efectivo. El declarante certifica que no hay información adversa no revelada y la sección de firma confirma el cumplimiento con las disposiciones de la Regla 144 y la Regla 10b5-1.

Dado el tamaño reducido de la transacción en relación con la capitalización de mercado y el flotante de MetLife, el aviso es principalmente administrativo y es poco probable que afecte la condición financiera de la empresa o el precio de las acciones.

MetLife, Inc. (MET)는 144 양식을 제출하여 2025년 6월 20일 Barclays Capital을 통해 547주의 보통주 매각을 제안했습니다. 제안된 매각의 총 시장 가치는 $42,966.85이며, 현재 유통 중인 671,297,826주와 비교할 때 약 0.00008%에 해당합니다.

신고서에는 지난 3개월 동안 MetLife 관련 계좌에서 총 686주를 판매하여 약 $55,392의 총수익을 올린 내역이 포함되어 있습니다. 취득 내역에 따르면 해당 주식은 2013-2014년에 Deutsche Bank로부터 현금으로 구매되었습니다. 신고자는 공개되지 않은 불리한 정보가 없음을 확인하며, 서명란에서는 Rule 144 및 Rule 10b5-1 규정 준수를 확인합니다.

MetLife의 시가총액 및 유통 주식 수에 비해 거래 규모가 매우 작기 때문에 이 공지는 주로 행정적인 성격이며 회사의 재무 상태나 주가에 영향을 미칠 가능성은 낮습니다.

MetLife, Inc. (MET) a déposé un formulaire 144 annonçant une vente proposée de 547 actions ordinaires via Barclays Capital le 20 juin 2025. La valeur marchande totale de la vente proposée s'élève à 42 966,85 $, comparée aux 671 297 826 actions actuellement en circulation, représentant environ 0,00008 % des actions en circulation.

Le dépôt indique des ventes antérieures au cours des trois derniers mois par divers comptes liés à MetLife totalisant 686 actions et des produits bruts d'environ 55 392 $. Les détails d'acquisition montrent que les actions ont été initialement achetées en 2013-2014 auprès de Deutsche Bank en espèces. Le déposant atteste qu'aucune information défavorable non divulguée n'existe, et la section de signature confirme la conformité avec les règles 144 et 10b5-1.

Étant donné la petite taille de la transaction par rapport à la capitalisation boursière et au flottant de MetLife, cet avis est principalement administratif et il est peu probable qu'il affecte la situation financière de la société ou le cours de l'action.

MetLife, Inc. (MET) hat ein Formular 144 eingereicht, in dem ein geplanter Verkauf von 547 Stammaktien über Barclays Capital am 20. Juni 2025 angekündigt wird. Der Gesamtmarktwert des geplanten Verkaufs beträgt 42.966,85 $, verglichen mit 671.297.826 ausstehenden Aktien, was etwa 0,00008 % der ausstehenden Aktien entspricht.

Die Einreichung listet frühere Verkäufe in den letzten drei Monaten durch verschiedene MetLife-nahe Konten auf, die insgesamt 686 Aktien und Bruttoerlöse von etwa 55.392 $ umfassen. Die Erwerbsdetails zeigen, dass die Aktien ursprünglich 2013-2014 von der Deutschen Bank gegen Barzahlung gekauft wurden. Der Einreicher bestätigt, dass keine nachteiligen, nicht offengelegten Informationen vorliegen, und der Unterschriftsbereich bestätigt die Einhaltung der Regel 144 und Regel 10b5-1.

Angesichts der geringen Größe der Transaktion im Verhältnis zur Marktkapitalisierung und zum Streubesitz von MetLife ist die Mitteilung hauptsächlich administrativer Natur und wird voraussichtlich weder den finanziellen Zustand des Unternehmens noch den Aktienkurs beeinflussen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schilling Robert David

(Last) (First) (Middle)
C/O C3.AI, INC.
1400 SEAPORT BLVD

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
C3.ai, Inc. [ AI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP & Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/26/2025 A 1,011,327(1) A $0 1,011,327 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement. 20% of each such RSU award shall vest on June 26, 2026 and 5% of each such RSU award shall vest on a quarterly basis thereafter, so long as the Reporting Person continues to provide services through such vesting dates.
/s/ Andrew Thomases, Attorney-in-Fact 06/30/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MetLife (MET) shares are being sold under this Form 144 filing?

547 common shares are slated for sale.

What is the estimated market value of the proposed MET share sale?

Approximately $42,966.85 based on the filing’s figures.

When is the expected sale date for the MET shares?

The filing lists an approximate sale date of 20 June 2025.

How does the sale size compare to MetLife’s shares outstanding?

It equals about 0.00008 % of the 671,297,826 shares outstanding.

Have there been recent sales by the same seller in the last 3 months?

Yes, a total of 686 shares were sold between March and June 2025 for roughly $55,392 in gross proceeds.
C3.Ai, Inc.

NYSE:AI

AI Rankings

AI Latest News

AI Latest SEC Filings

AI Stock Data

3.32B
121.07M
8.18%
54.55%
16.77%
Software - Application
Services-prepackaged Software
Link
United States
REDWOOD CITY